Related Experiment Video

Updated: Aug 21, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

[Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes]

Lan Zhang1, Xiehe Liu, Tao Li

  • 1Institute of Mental Health, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041 P.R. China. zhanglan@mail.sc.cninfo.net

Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics
|October 12, 2004
PubMed
Abstract

Insights

This study found no link between six genes and obsessive-compulsive disorder (OCD) drug response. However, the serotonin 2A receptor (5-HT2A) gene showed a difference in responders versus non-responders.

Area of Science:

  • Neuroscience
  • Genetics
  • Psychiatry

Background:

  • Obsessive-compulsive disorder (OCD) treatment often involves serotonin reuptake inhibitors (SRIs).
  • Genetic factors may influence individual responses to OCD pharmacotherapy.
  • Serotonin and dopamine pathways are implicated in OCD pathophysiology.

Purpose of the Study:

  • To explore associations between drug response in OCD patients and six functional genes.
  • To investigate the role of serotonin and dopamine-related genes in SRI treatment outcomes.

Main Methods:

  • 113 OCD families were recruited for the study.
  • Patients received 8-week SRI treatment, with responses assessed by Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
  • Genotyping of six genes (5-HT2A, 5-HTT, DRD2, DRD4, COMT, MAOA) and Transmission Disequilibrium Test (TDT) analysis were performed.

Main Results:

  • No significant associations were found between the six studied genes and differential drug response groups in OCD.
  • A significant difference was observed in homozygosity at the 5-HT2A -1438G/A locus between drug responders and non-responders (chi(2)=4.69, P=0.03).

Conclusions:

  • The serotonin 2A receptor (5-HT2A) gene may influence the efficacy of drug treatment for OCD.
  • Further research is warranted to elucidate the role of 5-HT2A in OCD pharmacogenetics.

More Related Videos

Marble Burying and Nestlet Shredding as Tests of Repetitive, Compulsive-like Behaviors in Mice06:50

Marble Burying and Nestlet Shredding as Tests of Repetitive, Compulsive-like Behaviors in Mice

Published on: December 24, 2013

Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging09:14

Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging

Published on: March 14, 2025

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...